Evidence map›Paper›PMID 30535969›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2019

Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab.

Salomon Y Cohen, Sandrine Tabary, Ala El Ameen, Sarah Mrejen, Gabriel Quentel, Audrey Giocanti-Auregan

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Flow pattern and perforating vessels in three different phases of myopic choroidal neovascularization seen by swept-source optical coherence tomography angiography.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Salomon Y CohenOphthalmology Center for Imaging and Laser, 11 rue Antoine Bourdelle, 75015, Paris, France. sycsyc75@gmail.com.ORCID http://orcid.org/0000-0003-1181-4379
Sandrine TabaryOphthalmology Center for Imaging and Laser, 11 rue Antoine Bourdelle, 75015, Paris, France.
Ala El AmeenDepartment of Ophthalmology, Paris Est University, Creteil, France.
Sarah MrejenOphthalmology Center for Imaging and Laser, 11 rue Antoine Bourdelle, 75015, Paris, France.
Gabriel QuentelOphthalmology Center for Imaging and Laser, 11 rue Antoine Bourdelle, 75015, Paris, France.
Audrey Giocanti-AureganDepartment of Ophthalmology, Hôpital Avicenne, AP-HP and Paris 13 University, Bobigny, France.
Centre Ophtalmologique d'Imagerie et de Laser · FRUniversité Paris-Est Créteil · FRUniversité Sorbonne Paris Nord · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate morphological changes in myopic choroidal neovascularization (mCNV) using optical coherence tomography-angiography (OCT-A) after treatment with ranibizumab.

methodsRetrospective analysis of consecutive patients over a 24-month period. All treatment-naïve mCNV were imaged at baseline with color pictures, spectral-domain OCT and OCT-A, and fluorescein angiography in selected cases. CNV morphology was classified at baseline and at 6 months. The CNV lesion surface was also compared.

resultsTwenty-nine patients with a mean age of 70.3 ± 10.1 years were included. They received a mean number of 2.65 injections over 6 months. Best-corrected visual acuity improved from 62.2 to 68.5 letters (p = 0.004), with regression of exudation in 24 eyes (82.7%). Baseline CNV was classified into tree-in-bud (16 eyes), medusa (9 eyes), or sea-fan (4 eyes) pattern. At 6 months, no abnormal blood flow was observed in CNV in 13 eyes. Eyes with complete regression or evolution towards an indistinct pattern showed more often a complete regression of exudation than eyes with unchanged pattern (p = 0.007). The mean CNV surface significantly decreased from 0.19 to 0.08 mm

conclusionAn unchanged pattern was more often associated with exudation persistence, while a complete regression or evolution towards indistinct pattern was always associated with vascular inactivity. However, variable changes in mCNV were observed after anti-VEGF. Thus, OCT-A could be more useful in the diagnosis than in the follow-up of mCNV.

Indexed as

AgedAngiogenesis InhibitorsChoroidChoroidal NeovascularizationDisease ProgressionDose-Response Relationship, DrugFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleMyopiaRanibizumabRefraction, OcularAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AAnti-VEGFChoroidal neovascularizationMyopiaOCT-angiographyRanibizumab

Identifiers

PMID30535969
OpenAlexW2904899482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.